Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -1.1x - -1.2x | -1.2x |
| Selected Fwd P/E Multiple | -0.2x - -0.3x | -0.3x |
| Fair Value | A$0.0025 - A$0.0027 | A$0.0026 |
| Upside | -38.1% - -31.6% | -34.8% |
| Benchmarks | - | Full Ticker |
| Kazia Therapeutics Limited | - | NasdaqCM:KZIA |
| Immuron Limited | - | ASX:IMC |
| Paradigm Biopharmaceuticals Limited | - | ASX:PAR |
| Alterity Therapeutics Limited | - | ASX:ATH |
| Dimerix Limited | - | ASX:DXB |
| BPH Global Ltd | - | ASX:BP8 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| KZIA | IMC | PAR | ATH | DXB | BP8 | |||
| NasdaqCM:KZIA | ASX:IMC | ASX:PAR | ASX:ATH | ASX:DXB | ASX:BP8 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | -30.8% | -89.4% | 79.2% | -61.1% | -114.5% | 32.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -707611.2% | -750.6% | -125344.1% | -8988.1% | -3571.4% | -198871.9% | ||
| Prior Fiscal Year | -2046500.0% | -209.8% | NA | -352.5% | -37520.9% | -1133569.9% | ||
| Latest Fiscal Year | -1079.3% | -141.5% | NA | -475.8% | -2926.4% | -1799.3% | ||
| Latest Twelve Months | -1079.3% | -112.4% | -87172.0% | -531.3% | -3159.0% | -947.8% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -0.3x | -1.5x | -5.6x | -2.5x | -9.3x | -2.2x | ||
| Price / LTM Sales | 3.2x | 2.5x | 8628.1x | 14.7x | 325.4x | 15.1x | ||
| LTM P/E Ratio | -0.3x | -2.2x | -9.9x | -2.8x | -10.3x | -1.6x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -10.3x | -2.8x | -0.3x | |||||
| Historical LTM P/E Ratio | -6.8x | -3.2x | -0.5x | |||||
| Selected P/E Multiple | -1.1x | -1.2x | -1.2x | |||||
| (x) LTM Net Income | (2) | (2) | (2) | |||||
| (=) Equity Value | 2 | 2 | 2 | |||||
| (/) Shares Outstanding | 608.3 | 608.3 | 608.3 | |||||
| Implied Value Range | 0.00 | 0.00 | 0.00 | |||||
| FX Rate: AUD/AUD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Upside / (Downside) | -29.2% | -25.5% | -21.8% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | KZIA | IMC | PAR | ATH | DXB | BP8 | |
| Value of Common Equity | 8 | 16 | 142 | 49 | 240 | 2 | |
| (/) Shares Outstanding | 5.6 | 233.5 | 389.4 | 5,491.0 | 558.4 | 608.3 | |
| Implied Stock Price | 1.40 | 0.07 | 0.37 | 0.01 | 0.43 | 0.00 | |
| FX Conversion Rate to Trading Currency | 1.59 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.88 | 0.07 | 0.37 | 0.01 | 0.43 | 0.00 | |
| Trading Currency | USD | AUD | AUD | AUD | AUD | AUD | |
| FX Rate to Reporting Currency | 1.59 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |